HopeStage
Back to all studies
CompletedNCT00254241

Quetiapine or risperidone for first-episode schizophrenia

About this titleRead the official source — NCT00254241
Medication studyAges 18–35United Kingdom
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 35 years.

Listed locations
LondonSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMay 2002
Recruitment status
Completed
Enrollment listed in the registry
80
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United Kingdom
Age range
From 18 Years to 35 Years
Official registry ID
NCT00254241
Official title
Show the full official title

Safety and Efficacy of Seroquel in First Episode Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

London

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Seroquel and Risperidone.

Who was this study for?

Listed age limits: 18 years to 35 years.

Want to explore more studies?

Explore studies